AnaptysBio

About:

AnaptysBio is a biotechnology company that develops antibody therapeutics based on somatic hypermutation.

Website: http://www.anaptysbio.com

Twitter/X: AnaptysBio

Top Investors: Sanofi, Cormorant Asset Management, Novo Holdings, Biotechnology Value Fund, Woodline Partners

Description:

AnaptysBio is a privately-held therapeutic antibody product company that uses of somatic hypermutation, or SHM, for antibody discovery and optimization. SHM is the body's natural process for generating potent antibodies to fight disease. The Company's SHM-Platform utilizes the key components of SHM and other techniques to generate antibodies for therapeutic applications through an iterative process of natural evolution and high-throughput selection a process that has been referred to as naturalizing antibodies. This versatile platform can be used both to discover and optimize antibodies directed at specific disease targets and also affinity mature existing antibodies to improve their binding properties. In addition to providing a more powerful approach to antibody discovery and protein optimization, it addresses a growing void in the therapeutic antibody field due to a string of acquisitions and licensing deals that have reduced the availability of many technologies.